Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 235.92M P/E - EPS this Y 82.40% Ern Qtrly Grth -
Income -20.23M Forward P/E -1.90 EPS next Y -339.30% 50D Avg Chg 13.00%
Sales 81.63M PEG -0.87 EPS past 5Y - 200D Avg Chg -34.00%
Dividend N/A Price/Book 0.80 EPS next 5Y 16.40% 52W High Chg -75.00%
Recommedations 2.70 Quick Ratio 21.84 Shares Outstanding 62.40M 52W Low Chg 70.00%
Insider Own 1.62% ROA -6.89% Shares Float 40.29M Beta 2.24
Inst Own 99.67% ROE -7.37% Shares Shorted/Prior 11.40M/8.15M Price 3.82
Gross Margin 9.02% Profit Margin -24.79% Avg. Volume 720,272 Target Price 5.29
Oper. Margin 65.62% Earnings Date Nov 5 Volume 367,973 Change 2.96%
About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics, Inc. News
11/15/24 Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)
11/14/24 Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...
11/13/24 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
11/12/24 Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
11/06/24 Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
10/25/24 Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
09:07 AM We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow
10/18/24 Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
10/11/24 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/09/24 Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
10/09/24 Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
10/07/24 FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
10/04/24 Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround
09/17/24 RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
09/16/24 Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
09/13/24 FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
09/12/24 Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
09/12/24 Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test
09/12/24 Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
09/10/24 Xencor Stock Gains 23% on Encouraging Pipeline Advancements
FULC Chatroom

User Image Luella_Salinas Posted - 20 hours ago

$CRBP $ETON $FULC LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? đź‘€ And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Mudwalk Posted - 1 day ago

$FULC Holy smokes---we are under 3? What is going on? is this stock in danger? I'm down so much money now. Any hope here.

User Image Mudwalk Posted - 4 days ago

$FULC The question is: Does this company have good things to look forward to? Is the story /outlook good? If so, worth holding onto shares despite recent tute dumping shares.

User Image Mudwalk Posted - 5 days ago

$FULC Yea---This may be the beginning of the end. If the tutes are selling it means that there are no gains to be made. Now I have to decide where I take the big hit or not. This is painful.

User Image Stradella Posted - 6 days ago

$FULC RTW Investments sold all shares: June 30, 2024 they had 9.3% https://finance.yahoo.com/quote/FULC/holders/ Today they filed 0% http://archive.fast-edgar.com/20241114/A42ZF2228222A9ZZ252U2ZOH479VZ222ZC62/

User Image Mudwalk Posted - 1 week ago

$FULC We why did we dip towards the end? Whats going on with this play? Do they have a good story?

User Image Stradella Posted - 1 week ago

$FULC No surprises on the ER, good or bad. Pretty much a nothing burger. 2 cohorts of the trial, with 10 patients in each. Very small, so the data probably will not have significant impact. Now it's a waiting game...

User Image Mudwalk Posted - 1 week ago

$FULC So----we popped to 4 and dumped. Must be some bad news we don't know. I don't get it.

User Image bologniesi Posted - 1 week ago

$FULC Any important news?

User Image DonCorleone77 Posted - 1 week ago

$FULC Fulcrum Therapeutics expects cash to fund operations into at least 2027 Based on its current operating plans, Fulcrum expects to end 2024 with approximately $240.0 million of cash, cash equivalents, and marketable securities, and expects its cash burn for the full year 2025 will be approximately $55.0 million to $65.0 million. Fulcrum also expects that its cash, cash equivalents, and marketable securities as of September 30, 2024 will be sufficient to fund its current operating requirements into at least 2027.

User Image DonCorleone77 Posted - 1 week ago

$FULC Fulcrum Therapeutics reports Q3 EPS (35c), consensus (41c) "In the third quarter, we made progress enrolling patients and activating new sites in the Phase 1b PIONEER trial of pociredir in sickle cell disease and advancing our preclinical pipeline," said Alex C. Sapir, Fulcrum's president and chief executive officer. "The need for effective therapeutic options for patients with sickle cell disease has become even more urgent due to the recent withdrawal of OXBRYTA globally. Based on the initial data generated in the Phase 1b trial, we believe that pociredir has the potential to increase fetal hemoglobin to levels that could ameliorate symptoms of sickle cell disease. While we were disappointed with the results of the Phase 3 REACH trial announced in September, we remain committed to improving the lives of patients with genetically defined diseases in areas of high unmet medical need like sickle cell disease. We are focused on progressing the development of pociredir as expeditiously as possible and remain on track to provide data from the PIONEER trial in 2025."

User Image Mudwalk Posted - 1 week ago

$FULC Hmm down 3% after hours. Someone is dumping bc they know something. Makes me wonder.

User Image Preston_Carr Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. Low Float only 29M outstanding shares. Any buy-in will make this fly to the moon. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead. 8.Offering Deal $ETON $FULC

User Image Mudwalk Posted - 1 week ago

$FULC ouch ouch---tutes selling this in blocks

User Image Mudwalk Posted - 2 weeks ago

$FULC We either rise to $7ish due to good results-or we dip and this becomes a real penny stock.

User Image Mudwalk Posted - 10/31/24

$FULC Only saving grace now is a fairly good ER with decent guidance. It will be about the guidance. If we get decent guidance then we may get new analyst price targets that will push this stock up.

User Image Mudwalk Posted - 10/29/24

$FULC Crap---this is definitely sinking to under $3. Just look at the trend.

User Image Mudwalk Posted - 10/26/24

$FULC Honestly, this stock is hoping on the SCD--that's the only thing on the pipeline. However, whatever they have for SCD is not good. They have previously placed a clinical hold and results have proven failure. And they mislead investors with previous drug. They knew results would be bad and lied about the possibility of commercialization which they knew would never happen.

User Image Mudwalk Posted - 10/25/24

$FULC More pain--

User Image Mudwalk Posted - 10/23/24

$FULC ouch----i'm down so much, its depressing

User Image Mudwalk Posted - 1 month ago

$FULC If Fulc abandoned the lopmapimod study which was a failure---why do they still have it listed on their official website? It's misleading.

User Image Mudwalk Posted - 1 month ago

$FULC Should crawl back to where it was or least half to where it was. Don't feel like the bad study results should of dropped this stock 60%.

User Image ChartGeek Posted - 1 month ago

@StocksAndhookers $FULC if prints above 3.62 today then you can hope for 5.50 range .. if not higher chances to crawl down

User Image Mudwalk Posted - 1 month ago

$FULC ANyone here know anything

User Image Mudwalk Posted - 1 month ago

$FULC Starting to believe that this can be in the $1 range until they come up with a SCD update which is not expected until 2025

User Image ChartGeek Posted - 1 month ago

@BallzofSTEAL New update on $FULC , with the breakdown below 3.38 today , expected to go to 1 range and then reverse and may move towards 5.50 range. So I got out of this trade and invested in $NVDA . Basically $FULC was my day trade the day I entered and since I didn't set up the stop loss ended up holding it loosing 1.30 cents per stock. One of my bad trades ..

User Image Mudwalk Posted - 1 month ago

$FULC This is making me sick. Everyday it's a 4-6% drop. This is going under 3 it seems. WTF. Someone is dumping bc they know something is not right.

User Image Mudwalk Posted - 1 month ago

$FULC Is 3.30's support or can we anticipate significantly more downside until we hear hopefully positive news on pioneer study. Have a lot of money riding on this play. Already down a lot and can't tolerate another leg drop.

User Image Mudwalk Posted - 1 month ago

$FULC Anyone is feelen a bit of optimism despite being down 60% from the 9's.

User Image Mudwalk Posted - 1 month ago

$FULC FMR LLC sold dumped 1.5 million shares, reducing their holdings by 50%. That's why we are now in mid 3.5's. Hope others don't follow suit.

Analyst Ratings
RBC Capital Sector Perform Sep 13, 24
HC Wainwright & Co. Neutral Sep 13, 24
Leerink Partners Market Perform Sep 12, 24
B of A Securities Underperform Sep 12, 24
Stifel Hold Sep 12, 24
Cantor Fitzgerald Neutral Sep 12, 24
B of A Securities Neutral Sep 9, 24
HC Wainwright & Co. Buy Aug 1, 24
Cantor Fitzgerald Overweight Jul 10, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Jan 20 Buy 13.00 1,923,076 24,999,988 11,609,704 01/24/23
Gould Robert J Interim President &.. Interim President & CEO Jan 13 Sell 15.00 6,766 101,490 499,864 01/13/23
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Dec 27 Buy 5.9941 4,089 24,510 9,505,925 12/29/22
Gould Robert J Director Director Jun 07 Option 7.84 71,435 560,050 578,065 06/08/22
Gould Robert J Director Director Jun 07 Sell 8.09 71,435 577,909 506,630 06/08/22
Gould Robert J Director Director Jun 02 Option 7.84 66,622 522,316 531,012 06/06/22
Gould Robert J Director Director Jun 02 Sell 7.99 66,622 532,310 506,630 06/06/22
Gould Robert J Director Director Apr 07 Option 7.84 5,631 44,147 512,261 04/11/22
Gould Robert J Director Director Apr 07 Sell 24.02 5,631 135,257 506,630 04/11/22
Gould Robert J Director Director Apr 01 Option 7.84 94,251 738,928 559,182 04/05/22
Gould Robert J Director Director Apr 01 Sell 24.1 94,251 2,271,449 506,630 04/05/22